We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Emerging Nosocomial Pathogen Isolated from Prosthetic Joint Infections

By LabMedica International staff writers
Posted on 10 Jan 2017
Further knowledge about the clinical and microbiological characteristics of prosthetic joint infections (PJIs) caused by different coagulase-negative staphylococci (CoNS) may facilitate interpretation of microbiological findings and improve treatment algorithms.

The implementations of new methods, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) or real-time broad-range polymerase chain reaction (PCR), has simplified the identification of CoNS to the species level.

A team of Swedish scientists working with those at the Linköping University (Sweden) performed retrospective cohort study included three centres and 21 patients with significant growth of Staphylococcus capitis during revision surgery for PJI between 2005 and 2014. More...
Clinical data were extracted and further microbiological characterisation of the S. capitis isolates was performed.

CoNS isolated in equal to or greater than two perioperative tissue samples obtained from revision surgery for hip or knee arthroplasties due to PJI were included for further analysis. If there were not at least two CoNS isolates with similar colony morphology and antimicrobial resistance pattern, the patient was excluded. MALDI-TOF MS was performed for species identification using a Microflex LT (Bruker Daltonik GmbH, Bremen, Germany).

To discriminate between the subspecies of S. capitis, urease activity and maltose fermentation tests were performed, using both tube test and API-ID32 STAPH (bioMérieux, Marcy l’Etoile, France). Standard antibiotic susceptibility testing by the disc diffusion test was also performed. The bioMérieux DiversiLab semi-automatic repetitive sequence-based PCR microbial genotyping system was used to detect the genomic fingerprints of each S. capitis isolate.

Ten patients experienced monomicrobial infections and among patients available for evaluation, 86% of chronic infections and 70% of early post-interventional infections achieved clinical cure; 90 % of monomicrobial infections remained infection-free. Multidrug-resistant S. capitis was detected in 28.6 % of isolates, methicillin resistance in 38.1 % and fluoroquinolone resistance in 14.3 %, but no isolates were rifampin-resistant. Heterogeneous glycopeptide-intermediate resistance was detected in 38.1 % and biofilm-forming ability was common.

The authors concluded that Staphylococcus capitis has the potential to cause PJIs, with infection most likely being contracted during surgery or in the early postoperative period. As S. capitis might be an emerging nosocomial pathogen, surveillance of the prevalence of PJIs caused by S. capitis could be recommended. The study was published in the January 2017 issue of the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:
Linköping University
Bruker Daltonik
bioMérieux

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.